What an FDG-PET Scan Measures, and Why the SUV Number Can Mislead

An FDG-PET scan does not photograph cancer. It maps where cells are consuming a radioactive glucose look-alike, and the SUV, or standardized uptake value, is a normalized brightness score for that consumption. Because inflamed tissue, infection, and several healthy organs also burn glucose, and because the number shifts with scanner settings, blood sugar, body size, and timing, a high SUV is a reason to look closer rather than a diagnosis.

What the tracer actually traces

FDG stands for fluorodeoxyglucose: an ordinary glucose molecule with a positron-emitting fluorine-18 atom swapped in for one hydroxyl group. Cells pull it in through the same membrane transporters that handle glucose, and the enzyme hexokinase tags it with a phosphate. The altered molecule then hits a dead end. It cannot continue down the glycolytic pathway and cannot easily exit the cell, so it piles up inside, a phenomenon known as metabolic trapping. Tissues with a heavy appetite for glucose accumulate more signal and appear brighter on the reconstructed image. Many malignancies qualify, which is why the scan earns its place in oncology. But as Chang and colleagues emphasized in the Korean Journal of Radiology (2006), FDG is not a cancer-specific agent, and that single fact drives most of the confusion around the images.

What the SUV number is

SUV is an attempt to turn brightness into something comparable between patients. The scanner measures radioactivity concentration in a region of interest, then divides it by the injected dose and scales for body weight. The result is a unitless ratio. Radiologists usually report SUVmax, the single hottest voxel in a lesion, though SUVmean and SUVpeak are also used. A value of 2.5 or above has long been treated as a rough flag for possible malignancy, but that threshold was never a bright line, and the source literature treats it as debated rather than settled. The number describes metabolic intensity. It does not identify what is causing that intensity.

Why benign tissue lights up

Activated immune cells are among the hungriest glucose consumers in the body. Neutrophils and macrophages recruited to fight infection or clear injured tissue ramp up glycolysis, so inflammation frequently mimics tumor on FDG-PET. Chang and colleagues catalog the usual culprits: tuberculosis, including a tuberculoma that reached an SUV of 4.3 in their series; sarcoidosis and other granulomatous disease; abscesses; and radiation-induced changes. Recent surgery, healing wounds, and reactive lymph nodes behave the same way.

Ordinary physiology adds more traps. Vangu and Momodu, writing in Frontiers in Nuclear Medicine (2022), describe how bowel routinely shows diffuse uptake from peristalsis, resident lymphoid tissue, and gut bacteria, how metformin can light up the colon dramatically in patients with diabetes, and how the urinary tract concentrates tracer as the kidneys clear it. Brown fat and resting skeletal muscle are further well-recognized sites of normal uptake. None of this is cancer, yet any of it can post an SUV in the range that would otherwise raise alarm.

The technical reasons the number drifts

Even for a fixed lesion, the SUV is not a fixed quantity. Several settings move it.

Blood glucose competes with FDG for the same transporters, so a high sugar level at injection lowers the tracer that reaches a tumor and can flatten its SUV. The EANM procedure guidelines (version 2.0), authored by Boellaard and colleagues, ask that patients fast for at least four hours and that plasma glucose sit below 11 mmol/L, roughly 200 mg/dL, before a clinical scan.

Timing matters just as much. FDG keeps accumulating in metabolically active tissue for well over an hour, so a lesion imaged later reads hotter than the same lesion imaged earlier. The EANM guideline sets an uptake interval near 60 minutes and asks that follow-up scans stay within about ten minutes of the original timing, precisely because drift here can masquerade as real change.

Body composition skews the scaling. Because fat is relatively quiet metabolically, weighting by total body weight inflates the SUV in heavier patients, which is why Chang and colleagues note that correction to lean body mass is needed before comparing scans across time. Lesion size cuts the other way: PET resolves detail down to roughly a centimeter, so smaller lesions suffer the partial-volume effect and read colder than they truly are. Scanner calibration, reconstruction settings, patient motion, and shine-through from a bright neighbor such as the bladder or kidney each nudge the figure further.

Making the number trustworthy

The practical lesson is not that SUV is useless. It is that a raw value carries little meaning without its context. A change in SUV on the same scanner, with the same preparation and timing, is far more informative than a single absolute reading, and this is why the EANM guidelines press so hard on standardization and cross-center harmonization. The number earns its weight only when it is anchored to the morphology on the paired CT, the patient's history, prior imaging, and, when the stakes call for it, tissue sampling. A hypermetabolic spot is a question. The answer lives in everything around it.

This is educational information about how an imaging biomarker behaves, not medical advice about any individual scan or diagnosis.